Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer
Pancreatic Neuroendocrine Neoplasm
Explore 7 assets in Pancreatic Neuroendocrine Neoplasm →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Fudan University
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05316480CT.gov Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Neuroendocrine Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer (this asset) | Fudan University | P2 | CCC · 53 |
| Lanreotide | Federation Francophone de Cancerologie Digestive | P2/3 | B |
| Ifa | Roswell Park Cancer Institute | P2 | CCC |
| Survaxm | Roswell Park Cancer Institute | P2 | CCC |
| Sargramostim | Roswell Park Cancer Institute | P2 | CCC |
| Alpelisib | Novartis Pharmaceuticals | P1 | CC |
| Exemestane | Novartis Pharmaceuticals | P1 | CC |
| Everolimus | Novartis Pharmaceuticals | P1 | CC |
| Gefitinib | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unk | D |
+2 more in the Pancreatic Neuroendocrine Neoplasm cohort
Other indications for Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Malignant Pancreatic Neoplasm | — | P4 | BBB · 76 |
| Adult Glioblastoma | — | P3 | BB · 64 |
| Pancreatic Neoplasm | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Humanized Mouse Monoclonal Hr3 .Beta.1 Chain Anti-Human Epidermal Growth Factor Receptor), Disulfide With Humanized Mouse Monoclonal Hr3 .Kappa.-Chain, Dimer in Pancreatic Neuroendocrine Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-humanized-mouse-monoclonal-hr3-beta1-chain-anti-human-epidermal-growth-factor-receptor-disulfide-with-humanized-mouse-monoclonal-hr3-kappa-chain-dimer-pancreatic-neuroendocrine-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →